Glioblastoma — clinical trials in Netherlands
18 open options
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE2RECRUITING
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
DNX-2401 — 2 sites
- TRIALEARLY_PHASE1RECRUITING
PET-imaging of Two Vartumabs in Patients With Solid Tumors
89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv · PET/CT scan — 1 site
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALPHASE3RECRUITING
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
TLX-101-Tx + Lomustine · TLX101-Tx — 9 sites
- TRIALNARECRUITING
Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI
Extended MRI — 4 sites
- TRIALNARECRUITING
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
Extended or additional MRI-scan (with contrast) prior to radiotherapy — 1 site
- TRIALNARECRUITING
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
Awake craniotomy · Craniotomy under general anesthesia — 5 sites
- TRIALPHASE2RECRUITING
Surgery for Recurrent Glioblastoma
Surgery followed by adjuvant second-line therapy · Second-line therapy alone — 25 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALNANOT_YET_RECRUITING
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan — 8 sites
- TRIALPHASE3RECRUITING
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Bevacizumab · Dexamethasone — 6 sites
- TRIALEARLY_PHASE1RECRUITING
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib · Lorlatinib with chemotherapy1 · Lorlatinib with chemotherapy 2 — 18 sites
- TRIALPHASE1RECRUITING
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
ONC206 · Standard of Care Radiation Therapy · Optional Proton (1H) MR spectroscopy (MRS) — 7 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALNARECRUITING
Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
Multimodal image-guided resection — 1 site
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.